MediWound Ltd. (MDWD) SEC Filings & Earnings Calls

Revenue decline due to timing of BARDA revenues and regional conflict-related shipment delays.

“decrease was primarily attributable to the timing of BARDA-related revenues, as well as postponed shipments related to regional conflict” · word for word

EscharEx Phase III enrollment progressing more gradually than anticipated; interim assessment expected by end of Q1 2027.

“Enrollment has progressed more gradually than originally anticipated” · word for word

Expanded NexoBrid manufacturing facility subject to regulatory approval; EMA pre-audit identified modifications needed.

“A recent on-site pre-audit by the European Medicines Agency (EMA) identified several recommended modifications” · word for word

Contract is with distributor Vericel; MediWound's revenue depends on Vericel's performance and BARDA's exercise of options.

“MediWound has not independently verified information reported by Vericel; contract includes optional awards.”

Revenue decline due to U.S. government shutdown and lower product sales to Vericel; reliance on government contracts.

“Revenue for 2025 totaled $17.0 million, compared to $20.2 million in 2024. The decrease was primarily attributable to the U.S. government shutdown.” · word for word

R&D expenses increased significantly due to EscharEx trial, widening operating loss.

“Research and development expenses increased to $14.3 million from $8.9 million in 2024.” · word for word

EscharEx Clinical Trial Risk

“The development of EscharEx for the debridement of chronic and other hard-to-heal wound indications is in Phase II studies, and there is no certainty that EscharEx will achieve all of the objectives of the trials as required or that the FDA will allow at this stage to initiate further studies or that we will successfully complete the development to obtain a ” · word for word

BARDA Contract Expiration

“The BARDA Contract expired in September 2025.” · word for word

Manufacturing Regulatory Approval Risk

“The expanded NexoBrid manufacturing facility is now fully operational, increasing production capacity sixfold to support growing global demand; market availability remains subject to completion of regulatory reviews and approvals, which are expected in 2026.” · word for word

Potential dilution from increased share reserve, but no immediate financial impact.

“Increase of 300,000 ordinary shares reserved for issuance under 2024 Share Incentive Plan.”

Revenue recognition delays due to U.S. government shutdown impacted Q4 2025 results.

“U.S. government shutdown–related delays impacted revenue recognition in our fourth quarter results.” · word for word

Guidance assumes continued BARDA and DoD support; any disruption could impact revenue trajectory.

“All guidance periods assume continued support from BARDA and the U.S. Department of Defense.” · word for word

EscharEx regulatory approval required for 2028 revenue contribution; clinical trial risk.

“The 2028 outlook also assumes a potential initial contribution related to EscharEx, subject to regulatory approval.” · word for word

Clinical trial risk: EscharEx Phase III enrollment ongoing, interim analysis pending.

“Enrollment continues in VALUE Phase III study; pre-specified interim sample-size assessment planned after 65% of patients complete treatment.”

Operating loss widening due to increased R&D and SG&A expenses.

“Operating loss increased to $6.5M from $5.1M, driven by higher R&D ($3.5M vs $2.5M) and SG&A ($4.0M vs $3.2M).”